[PRESS RELEASE] – VANCOUVER, British Columbia, March 27, 2026 – HYTN Innovations Inc., a pharmaceutical manufacturer specializing in products containing psychoactive and psychotropic compounds, including cannabis, announced that wholesale cannabis products previously exported to Germany during the prior quarter have now been successfully released for sale in the German market.
The release follows completion of required import, quality control and market release procedures for Germany’s regulated medical cannabis market. Following this milestone, the company has accepted a reorder for additional wholesale product.
This milestone builds on HYTN’s previously announced strategic supply framework for Germany and further demonstrates the company’s ability to execute within highly regulated international medical cannabis markets.
“The successful release of product into the German market is a significant commercial milestone,” HYTN CEO Elliot McKerr said. “It validates that our GMP platform meets the stringent requirements of one of the world’s most tightly regulated medical cannabis markets. The acceptance of a reorder is a positive indicator as we continue toward building recurring international revenue channels.”
HYTN believes the successful German market release of this shipment further validates the commercial progress reflected in its recent financial results and supports the company’s strategy of expanding pharmaceutical-grade cannabis sales into highly regulated international markets.
